New science and Alzheimer’s disease: Editing the DNA blueprint of brain cells

Jerold Chun, M.D., Ph.D.
Jerold Chun, M.D., Ph.D. with Lawrence Family Jewish Community Center & SBP logos overlayed

Date and time

September 16, 2020

2:00 PM - 3:00 PM


Virtual Event

Partnering with  Lawrence Family Jewish Community Center logo


Alzheimer’s disease is the most common cause of dementia. No effective medicines currently exist, which is partly due to our incomplete understanding of the human brain—which has been thought to arise from a single DNA blueprint: our genome. However, it is now clear that the blueprint within each brain cell can be different. Recent research has identified an editing process called “somatic gene recombination (SGR),” which can alter genes within a cell. Disruption of this process may underlie Alzheimer’s disease. Knowledge of how SGR works is providing opportunities for near-term treatment of Alzheimer’s using existing FDA-approved medicines that have decades of safety data, providing a new option for patients.



Jerold Chun, M.D., Ph.D.

Degenerative Diseases Program

Senior Vice President
Neuroscience Drug Discovery
Neuroscience and Aging Research Center